Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-16), Redcare Pharmacy NV's 12-1 Month Momentum % is N/A%.
The industry rank for Redcare Pharmacy NV's 12-1 Month Momentum % or its related term are showing as below:
XSWX:RDC's 12-1 Month Momentum % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: -13.54 * Ranked among companies with meaningful 12-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Redcare Pharmacy NV 12-1 Month Momentum % Related Terms
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Redcare Pharmacy NV (XSWX:RDC) has a 12-1 Month Momentum % of N/A% as of Aug. 16, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Redcare Pharmacy NV and its competitors. According to the industry distribution chart, Redcare Pharmacy NV ranks #468 out of 661 companies in the Healthcare Providers & Services industry, placing it in the top 70.8%.
Is Redcare Pharmacy NV's 12-1 Month Momentum % too high?
Redcare Pharmacy NV's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Redcare Pharmacy NV ranks #468 out of 661 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Redcare Pharmacy NV has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Redcare Pharmacy NV's 12-1 Month Momentum % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Redcare Pharmacy NV ranks #468 out of 661 companies for 12-1 Month Momentum %. This places Redcare Pharmacy NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Healthcare Providers & Services company?
A good 12-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Redcare Pharmacy NV and its competitors. Redcare Pharmacy NV's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redcare Pharmacy NV stock overvalued right now?
Based on GuruFocus' analysis, Redcare Pharmacy NV (XSWX:RDC) is currently considered Possible Value Trap. The stock's GF Value™ is CHF159.85, compared to a current price of CHF58.05 — trading 63.7% below its estimated fair value. The current 12-1 Month Momentum % is N/A%. Redcare Pharmacy NV's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Redcare Pharmacy NV (XSWX:RDC), the current 12-1 Month Momentum % is N/A% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Redcare Pharmacy NV (XSWX:RDC) Overvalued in 2026?
Based on GuruFocus' analysis, Redcare Pharmacy NV stock appears to be undervalued.
The current stock price of CHF58.05 is trading 63.7% below its estimated GF Value™ of CHF159.85.
GuruFocus considers Redcare Pharmacy NV to be Possible Value Trap.
Key valuation signals for XSWX:RDC:
12-1 Month Momentum %: N/A%
GF Value™: CHF159.85 vs. price of CHF58.05 (63.7% below fair value)
No single metric tells the full story. See the XSWX:RDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Redcare Pharmacy NV is an online pharmacy business for prescription and nonprescription (over-the-counter) pharmaceuticals, beauty and personal care products (BPC) and food supplements. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands. It operates in two segments, namely DACH segment that includes sales in Germany, Austria and Switzerland; and the International segment that includes sales across Belgium, the Netherlands, France and Italy. The DACH segment accounts for the majority of the revenue.
46GF Score
Get the complete analysis for XSWX:RDC
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RDC has been successfully added to your 
